Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Stage 4 Metastatic NSCLC

Phase 1

Recruiting

• Conditions: Carcinoma, Non-Small-Cell Lung Cancer
• Interventions: Biological: KB-GDT-01

• Registration Number: NCT06069570
• Lead Sponsor: Kiromic BioPharma Inc.

Brief Summary

This is a clinical trial studying intravenous infusions of allogeneic gamma delta T cells after receiving low dose radiotherapy in participants with metastatic non-small cell lung cancer to evaluate the safety and efficacy of combining immunotherapy with radiation therapy.

Detailed Description

In this clinical trial, or 'study', participants with stage 4, non-small cell cancer (NSCLC), will receive KB-GDT-01, an allogeneic (cells from healthy donors) gamma delta T-cell product. All participants will receive KB-GDT-01 as intravenous infusions in combination with radiotherapy.

After being informed about the study and its potential risks, during the 28-day screening period, all consented participants will have laboratory tests, assessments, tumor scans, and a tumor biopsy.

Cytokine release syndrome symptoms and other potential adverse effects, will be monitored during the dose limiting toxicity period.

The study will be conducted in 2 parts, with the same number of visits in each part.

In Part 1 Dose Escalation, the study will attempt to identify the best dose with the lowest incidence of adverse effects (AE) and try to identify if the KB-GDT-01 is working (effectiveness). In Part 2 Dose Expansion the best dose will be further investigated for AE and effectiveness. There will be up to 36 participants in Part 1 and up to 12 additional participants in Part 2 of the study.

The total treatment cycle of the study drug protocol will be completed in 10 days. Participants will then attend clinic visits during a 30-day short-term follow-up period, with a subsequent long-term follow-up period up to Month 24

Study Timeline

• Study First Submitted: 2023-09-29
• Study First Submitted QC: 2023-09-29
• Study First Posted: 2023-10-06
• Study Start: 2023-11-07
• Status Verified: 2024-08
• Last Update Submitted: 2024-08-19
• Last Update Posted: 2024-08-21
• Primary Completion: 2024-10
• Study Completion: 2027-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 48

Inclusion Criteria

• Signed and dated informed consent form.
• Male or female, > 18 years old.
• Minimum body weight of 50 kilograms (kg).
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
• Histologically or cytologically confirmed stage 4 metastatic NSCLC
• Progressed on at least 2 lines of SOC therapy including platinum-based chemotherapy and immune checkpoint inhibitors.
• Genomic screening, with tumors with known actionable molecular alterations, such as EGFR, ALK, ROS-1, BRAF, RET, MET, and KRAS etc., must have progressed on appropriate target-directed molecular therapy.
• At least one measurable target lesion based on RECIST v1.1
• All toxicity associated with previous treatments are recovered to CTCAE grade of ≤1, except for continuing alopecia.
• Life expectancy of at least 6 months.
• Adequate hematopoietic, hepatic and renal function
• Agree to adequate contraception for up to 120 days after the last dose of study drug.
• Negative serum pregnancy test for women of childbearing potential

Read More

Exclusion Criteria

• Chemotherapy, investigational, and/or check-point inhibitor therapy within the 30 days prior to study Day 1.
• Major surgery, except for vascular access placement, within the 30 days prior to study Day 1.
• Active autoimmune disease requiring immunosuppressive therapy.
• Infection requiring systemic treatment within 30 days prior to study Day 1.
• History of peritoneal effusion (ascites), pericardial, or pleural effusions/nodules.
• Uncontrolled hypertension, history of arrhythmia including atrial fibrillation, unstable angina, decompensated congestive heart failure, cardiac ejection fraction ≤ 50%, myocardial infarction, or marked baseline prolonged QT/QTc intervals.
• Human immunodeficiency virus (HIV), Hepatitis B, or Hepatitis C detection.
• Participation in the treatment portion of a clinical trial or completed a clinical trial within the 30 days prior to the first dose of KB-GDT-01.
• Presence of any condition that may, in the opinion of the Investigator, render the patient inappropriate from participating in the study.
• Breastfeeding or pregnant female, or patient is expecting to conceive or father children during the study.
• Allergy or intolerance to any of the study product ingredients or excipients.
• Live vaccines administered within 30 days prior to study Day 1.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
KB-GDT-01 cells	KB-GDT-01	Dose Level 1: 400 x10\^6, 800 x10\^6 or 1600 x10\^6 KB-GDT-01 cells + radiation (1.0 Gy/fraction)

Primary Outcome Measures

Name	Time	Method
Number of participants with Adverse Events (AE) and/or Dose Limiting Toxicities (DLT) as a Measurement of Safety and Tolerability of KB-GDT-01 in Combination with LDRT	From the first infusion of study drug until Day 40 or 30 days after the last study drug infusion, whichever occurs later	DLT, defined as the occurrence or start of a clinically significant Grade 3 or greater AE (per CTCAE v5.0) occurring during the DLT assessment period that cannot be attributed to disease progression, intercurrent illness, or concomitant medication.

Secondary Outcome Measures

Name	Time	Method
Objective Response Rate (ORR)	From first study drug infusion through to Month 24	Investigator assessed ORR per RECIST v1.1. ORR is defined as the percentage of participants with a best overall response of complete or partial response.
Progression Free Survival (PFS)	From first study drug infusion until the first evidence of disease progression, death or Month 24.	Investigator assessed PFS per RECIST v1.1. PFS is defined as the time from first study drug infusion until the first evidence of disease progression or death.
Time to Progression (TTP)	From first study drug infusion until first evidence of disease progression or Month 24.	Investigator assessed TTP per RECIST v1.1. TTP is defined as the time from first study drug infusion until first evidence of disease progression.
Overall Survival (OS)	From first study drug infusion until death or Month 24.	Investigator assessed OS per RECIST v1.1. OS is defined as the time from first study drug infusion to death.
Time to Treatment Response (TTR)	From first study drug infusion until first evidence of disease response or Month 24.	Investigator assessed TTR per RECIST v1.1. TTR is defined as the time from first study drug infusion until first evidence of disease response.
Disease Control Rate (DCR)	From first study drug infusion until first evidence of disease response or stable disease or Month 24.	Investigator assessed DCR per RECIST v1.1 DCR is defined as the percentage of participants with complete response, partial response or stable disease.

Trial Locations

Locations (5)

The University of Arizona Cancer Center; 🇺🇸 Tucson, Arizona, United States

Beverly Hills Cancer Center; 🇺🇸 Beverly Hills, California, United States

Texas Oncology - Tyler; 🇺🇸 Tyler, Texas, United States

UPMC Hillman Cancer Center; 🇺🇸 Pittsburgh, Pennsylvania, United States

Virginia Oncology Associates; 🇺🇸 Norfolk, Virginia, United States